Psoriatic Arthritis

One-year results from the PsABio study provide evidence on factors that may impact treatment selection and decisions in clinical practice.

“Biomarkers can be used to elucidate normal and pathological processes and to measure biological response to a therapeutic intervention,” investigators stated.

In this Q&A, Gerd R. Burmester, MD, discussed the findings of his study that evaluated the exposure to ixekizumab, outcomes and medical history of patients with active psoriatic arthritis (PsA) who experienced adverse events.

Jeffrey Stark, MD, discusses the latest bimekizumab and certolizumab pegol data presented at the 2022 American Academy of Dermatology annual meeting.

A notable percentage of patients with rheumatic diseases, such as psoriatic arthritis, stop taking bDMARDs due to lack of effectiveness and adverse events.

As quality of life (QoL) in patients with psoriatic arthritis (PsA) is significantly lower when compared with patients with psoriasis, one of the main goals of treating PsA is improving QoL.

Understanding the differences between sexes regarding PsA treatment may change the management of PsA in male and female patients and improve outcomes.

“Although the achievement of treatment targets has been associated with improved quality of life and slower disease progression, patients may still experience symptoms and a burden of disease,” investigators stated.

Dietary counseling could play an important role in the treatment of patients with psoriatic arthritis, contributing to better disease activity control.

The survey found 42% of patients with psoriatic disease had never discussed treatment goals with their provider, and less than half of patients with psoriatic arthritis were treated by a rheumatologist.

ACR20 response was significantly higher in patients receiving either deucravacitinib 6 mg daily or 12 mg daily when compared with placebo.

Patients treated with ixekizumab had higher rates of simultaneous complete skin and nail clearance compared with etanercept, ustekinumab and adalimumab.

Furthermore, psoriatic treatment did not appear to significantly reduce COVID-19 vaccine efficacy.

Patients with psoriatic arthritis and ankylosing spondylitis experienced rapid pain reduction with upadacitinib, regardless of treatment history.

John Tesser, MD, closes the discussion with unmet needs in the PsA treatment landscape, as well as what he hopes to see in the future.

Expert panelists share tips for boosting patient compliance among patients with psoriatic arthritis.

Three colleagues share insights into their evolving approaches regarding the management of patients with psoriatic arthritis who test positive for COVID-19.

John Tesser, MD; Nehad Soloman, MD; and Jennifer Simpson, DNP, emphasize the important of vaccination against COVID-19 for patients with psoriatic arthritis.

A panel of experts and colleagues recall the indicators and steps that need to be taken when changing PsA therapies.

“Incorporating patient perspectives will not only help better tailor therapies in this heterogeneous population but also identify treatment targets that are relevant to the individual patients," investigators explained.

Three experts discuss measurement of outcomes for psoriatic arthritis management and what a “successful” treatment looks like.

John Tesser, MD; Nehad Soloman, MD; and Jennifer Simpson, DNP, profile classes of interleukin inhibitors and the potential benefits for patients with psoriatic arthritis.

Soumya D. Chakravarty, MD, PhD, discusses the growing body of clinical evidence evaluating joint efficacy, safety, and patient-reported outcomes in patients with psoriatic arthritis receiving guselkumab.

Free or total 25(OH)D serum levels were not associated with psoriasis disease severity in this small study of biologic-naïve patients.

Before closing out their discussion on psoriatic arthritis management, two experts consider how the COVID-19 pandemic has affected their practice.